The synthesis of well-defined polypeptides show complex macromolecular architecture requires the use of monomers that can be grouped by orthogonally grouped, containing primary amines that will be used as initiary for polymerization of the ring opening (ROP) anhydride n-carboxy. Synthesis and characterization of novel nε-9-fluorylmethoxycarbony-ls-carboxy anhydride (Na-FMOC-Lysine NCA), as well as linear poly novel (Nε-FMOC-L-Lys) n homopipeptide and poly (L-lysine) 78- Block- [Poly (L-Lysine) 10-graft-poly (L-Histidine) 15] Copolypeptide block-graft, served.
The copolypeptide graft synthesis was carried out through the NA-BOC-L-Lysine NCA ROP when using n-hexylamine as an initiator, followed by the polymerization of NCA Nε-FMOC-L-lysine. The latest blocks are selectively explored in basic conditions, and the resulting ε-amine is used as an initiation species for ROP NIM-Trity-L-Histidine NCA. Finally, the Board of Commissioners and Trt groups were sentenced by TFA. High vacuum techniques are applied to achieve the conditions needed for well-defined polypeptide synthesis. Molecular characterization shows that polypeptides show molecular homogeneity and high composition.
Finally, dynamic light scattering, ζ-potential, and a circular crocated measurement is used to investigate the ability of polypeptides to gather itself in different conditions. This monomer paves the way for polypeptide synthesis with complex macromolecular architecture that can define aggregation behavior, and, therefore, can cause the synthesis of responsive nanocarrier “smart” stimulation for controlled drug delivery applications.
Antimicrobial multifunctional polypeptide-selenium nanoparticles combating drug resistance bacteria
Antibiotic-resistant bacteria are severe threats to human health. The global global surveillance system of the Health Health Health has revealed antibiotic resistance between half a million patients in 22 countries, with Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae became the most resistant species. Antimicrobial nanoparticles emerged as an alternative that promised antibiotics in the fight against antimicrobial resistance. In this work, selenium nanoparticles are coated with antimicrobial polypeptides, ε-poly-licin, (SE np-ε-pl) synthesized and antibacterial activity and cytotoxicity investigated. SE NP-ε-PL which shows significantly larger antibacterial activity of all eight species of bacteria tested, including gram-positive, gram-negative strains, and drug resistance, than their individual components, SE NP and ε-pl.
Nanoparticles do not show toxicity to human dermal fibroblasts at the minimum inhibitory concentration, showing therapeutic windows. Furthermore, unlike conventional kanamycin antibiotics, SE NP-ε-PL does not easily induce resistance to E. coli or S. aureus. In particular, S. aureus began developing resistance to Kanamycin from the generation of ~ 44, while needed ~ 132 generations for resistance to develop into SE np-ε-pl. Surprisingly, E. coli cannot develop resistance to nanoparticles above ~ 300 generations. These results indicate that the multifunctional approach to combining SE NP with ε-PL to form SE NP-ε-PL is a new strategy that is very efficacious with the antibacterial activity of the width spectrum, low cytotoxicity, and significant delay in the development of resistance.
Open polypeptides open surface are successfully used as targets to develop a one-step prototype immunochromatography strip for specific and sensitive direct detection of staphylococcus aureus which causes neonatal sepsis
Neonatal sepsis is a life-threatening condition and Staphylococcus aureus is one of the main causes. However, until now, there are no fast and sensitive diagnostic tools have been developed for direct detection. Bioinformatics analysis identifies 112 amino acid polypeptides exposed to the surface of the cell protein nwmn_1649 cell walls, surface protein involved in cell aggregation and biofilm formation, as specific species and moiety which is highly preserved.
Polypeptides are cloned, purified, and used to immunize mice to increase certain immunoglobulin. Purified antibodies are conjugated to gold nano particles and are used to assemble immunochromatographic strips (ICS). The prototype IC developed is detected as low as 5 μg of pure polypeptides and 102 CFU / ML S. aureus in 15 minutes. The strip shows superior ability to directly detect S. aureus in the blood specimens of neonatal sepsis without previous sample processing. In addition, it does not show cross reactions in specimens infected with two other main causes of neonatal sepsis; Koagulase-negative Staphylococci and Klebsiella pneumoniae. The selected NWMN_1649 polypeptide shown shows success as a promising biomolecule where IC prototypes have been developed. This ICS provides fast, direct, sensitive and specific options for S. aureus detection which causes neonatal sepsis. Such tools are needed especially in limited countries of resources.
Stabilization of oil emulsion in soybean water using multilayers polypeptides: cationic polylysine and anionic acid polyglutamate
Oil-in-water emulsions are used as a shipping system for non-polar functional materials in various industries, including food, cosmetics, personal care products, agrochemicals and pharmaceuticals. However, emulsions tend to be damaged in conditions found in many commercial products. In this study, the functional performance of lipid droplets in emulsions is adjusted to electrostatic deposition of layers after the sequential layers of charged polypeptides contrary to their surface. Cationic Poly-L-lysine (PLL) and anionic poly-glutamic acid (PGA) are used as a pair of polypeptides imposed on the opposite (pH 4.0).
First, the primary emulsion (10% W / W soybean oil emulsion) is formed consisting of small lipid droplets (D32 = 500 μm) coated by natural surfactants (0.05% w / w Quilleta Saponin). Second, Cationic PLL is saved to the surface of anionic saponin-plated droplets. Third, Anionic PGA was saved to the surface of the cationic PLL-Saponin-plated droplets. We then assess the ability of coatings to protect lipid droplets from aggregation when pH (2.0-9.0), ionic power (0-350 mm), or temperature (30-90 ° C) changed. Primary, secondary and tertiary emulsion properties are monitored by measuring the average particle diameter (D32), electrical characteristics (ζ-potential), and micro from lipid droplets.
TAT Peptide |
|||
| abx266559-200l | Abbexa | 200 µl | EUR 237.5 |
TAT peptide |
|||
| HY-P0282 | MedChemExpress | 10mg | EUR 1398 |
TAT peptide |
|||
| MBS5763704-10mg | MyBiosource | 10mg | EUR 765 |
TAT peptide |
|||
| MBS5763704-1mg | MyBiosource | 1mg | EUR 190 |
TAT peptide |
|||
| MBS5763704-5mg | MyBiosource | 5mg | EUR 485 |
TAT peptide |
|||
| MBS5763704-5x10mg | MyBiosource | 5x10mg | EUR 3305 |
TAT peptide |
|||
| TP1451-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: TAT peptide |
|||
TAT peptide |
|||
| TP1451-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: TAT peptide |
|||
TAT peptide |
|||
| TP1451-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: TAT peptide |
|||
TAT peptide |
|||
| TP1451-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: TAT peptide |
|||
TAT peptide |
|||
| TP1451-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: TAT peptide |
|||
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
| 047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
| 047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
| 047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
FGL Peptide - Cy3 Labeled |
|||
| FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
FGL Peptide - Cy5 Labeled |
|||
| FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
FGL Peptide - FAM Labeled |
|||
| FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
Pedal Peptide (Pep) (Aplysia) |
|||
| 047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
ExE peptide M3mP6 mutant |
|||
| 064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
| 064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
AF-16 Peptide - Antibody |
|||
| H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
FGL Peptide - FITC Labeled |
|||
| FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
Schizophrenia Related Peptide |
|||
| 047-79 | PHOENIX PEPTIDE | 5 mg | EUR 44.28 |
Insulin B (22-25) Peptide |
|||
| 035-08 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
Eosinophilotactic Peptide (AGSE) |
|||
| 070-28 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Eosinophilotactic Peptide (VGSE) |
|||
| 070-29 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Cell Penetrating ARF Peptide (26-44) |
|||
| 068-56 | PHOENIX PEPTIDE | 500 μg | EUR 640.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
| RK-064-01 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
FGL Peptide - Biotin Labeled |
|||
| B-073-36 | PHOENIX PEPTIDE | 20 μg | EUR 405 |
Peptide F (Bovine) - Antibody |
|||
| H-024-58 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Brain Peptide (Bees) Library |
|||
| L-007 | PHOENIX PEPTIDE | 51 peptides | EUR 6456.24 |
Gastrointestinal Peptide Library |
|||
| L-006 | PHOENIX PEPTIDE | 200 peptides | EUR 7267.32 |
Peptide R / CXCR4 Antagonist |
|||
| 030-25 | PHOENIX PEPTIDE | 200 μg | EUR 203.04 |
PGMtide Peptide - Cy3 Labeled |
|||
| FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Peptide - FAM Labeled |
|||
| FG-040-69A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
| 033-34 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
| H-064-07 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
[D-Ala1]-Peptide T amide |
|||
| 057-03 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
Peptide F (Bovine) - RIA Kit |
|||
| RK-024-58 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Calmodulin Binding Peptide 1 |
|||
| 070-17 | PHOENIX PEPTIDE | 20 μg | EUR 214.92 |
Catch-Relaxing Peptide (CARP) |
|||
| 047-20 | PHOENIX PEPTIDE | 1 mg | EUR 199.8 |
FGL Peptide - Rhodamine Labeled |
|||
| FR-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 537.84 |
Peptide-Depleted Plasma (Rat) |
|||
| MB-099-02 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
| RK-064-07 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Glycogenolysis-Inhibiting Peptide |
|||
| 023-63 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Anti-Inflammatory Peptide 1 |
|||
| 004-01 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 2 |
|||
| 004-02 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 3 |
|||
| 004-03 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Urokinase-Derived Peptide A6 |
|||
| 025-12 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide - Biotin Labeled |
|||
| B-040-69 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
TAT Derivative, R9-Tat |
|||
| 068-27 | PHOENIX PEPTIDE | 500 μg | EUR 370.44 |
Peptide 34 / GPR-54 Agonist |
|||
| 048-94 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
FGL Peptide - I-125 Labeled |
|||
| T-073-36 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Peptide-Depleted Plasma (Human) |
|||
| MB-099-01 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
| FG-064-07A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
| T-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
F3 Peptide / HMGN2 Fragment 3 |
|||
| 004-12 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Myosin Kinase Inhibiting Peptide |
|||
| 058-20 | PHOENIX PEPTIDE | 500 μg | EUR 50.76 |
Antimicrobial Trp-rich peptide |
|||
| 004-05 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Fibronectin CS1 Peptide (EILDVPST) |
|||
| 025-20 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Peptide YY (PYY) (3-36) (Human) |
|||
| 059-02 | PHOENIX PEPTIDE | 200 μg | EUR 102.6 |
Peptide YY (PYY) (Human) - Antibody |
|||
| H-059-01 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
PGMtide Peptide - Rhodamine Labeled |
|||
| FR-040-69 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
Anti-Angiogenic Peptide Library |
|||
| L-008A | PHOENIX PEPTIDE | 88 peptides | EUR 6067.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
| G-064-01 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Peptide A / p60v-src (137-157) |
|||
| 058-21 | PHOENIX PEPTIDE | 500 μg | EUR 135 |
pro-Opionmelanocortin / J Peptide |
|||
| 022-22 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Cancer-Targeting Peptide Library |
|||
| L-015 | PHOENIX PEPTIDE | 289 peptides | EUR 7253.28 |
C28 optimized peptide 6 (Human) |
|||
| 073-82 | PHOENIX PEPTIDE | 100 μg | EUR 235.44 |
The electrical characteristics of droplets can be modulated by controlling the number and type of layer used. Primary emulsions have the best resistance to various environmental conditions, while secondary emulsions have the worst, suggest electrostatic deposits may only be used to get certain functions. Interestingly, PLL regardless of the surface of the secondary emulsion at high salt concentrations due to electrostatic screening, which increases their salt stability. This phenomenon may be useful for several food applications, eg, have cationic droplets during food storage, but are anionic in the human body.
